{"id":3765,"date":"2019-09-04T17:09:01","date_gmt":"2019-09-04T15:09:01","guid":{"rendered":"https:\/\/www.modag.net\/modag-appoints-dr-johannes-levin-as-chief-medical-officer\/"},"modified":"2025-06-03T12:26:27","modified_gmt":"2025-06-03T10:26:27","slug":"modag-appoints-dr-johannes-levin-as-chief-medical-officer","status":"publish","type":"post","link":"https:\/\/www.modag.net\/en\/modag-appoints-dr-johannes-levin-as-chief-medical-officer\/","title":{"rendered":"MODAG Appoints Dr. Johannes Levin as Chief Medical Officer"},"content":{"rendered":"

WENDELSHEIM, Germany, September 4, 2019<\/b><\/p>\n<\/div>

MODAG today announced the appointment of Johannes Levin, M.D., as Chief Medical Officer (CMO). Dr. Levin brings with him over ten years of experience in the field of movement disorders, particularly in atypical Parkinsonism such as Multiple System Atrophy (MSA), along with a strong scientific background in protein aggregation.<\/h2><\/div>

He recently led a clinical MSA study with Prof. Dr. Armin Giese, CSO of MODAG; the findings were published in The Lancet Neurology<\/a>. At MODAG, Dr. Levin will be responsible for advancing the company\u2019s lead candidate, anle138b, into the clinic. He will report to Dr. Torsten Matthias, CEO of MODAG. <\/p>\n

\u201cAs an expert in MSA and protein aggregation, Dr. Levin is a valuable addition to the MODAG team,\u201d commented Dr. Torsten Matthias, CEO of MODAG. \u201cWith Dr. Levin as our CMO, we are in an excellent position to move into clinical evaluation under the direct supervision of a respected and experienced movement disorder specialist. We believe his official appointment to our company underscores MODAG\u2019s potential in the neurodegenerative disease space.\u201d <\/p>\n

Commenting on his appointment, Dr. Johannes Levin, CMO of MODAG said: \u201cMODAG is an exciting company with an innovative pipeline including compounds that offer the potential to be disease-modifying, which are urgently needed in neurodegenerative diseases. My previous work with MSA has solidified my understanding of the unmet need for a disease-altering drug for patients living with parkinsonian disorders like MSA and Parkinson\u2019s disease; I believe MODAG has the opportunity to address this challenge as we move into the clinic.\u201d <\/p>\n

Dr. Levin is a Group Leader in the Neurodegenerative Diseases Group of the Department of Neurology of the Ludwig Maximilian University of Munich (LMU) and at the German Center for Neurodegenerative Diseases (DZNE). He has a proven track record for coordinating and leading academic research studies as well as industry-sponsored clinical trials. Dr. Levin serves as Principal Investigator to many clinical studies including the largest interventional MSA trial in Germany<\/span>

and international cohort studies such as the Dominantly Inherited Alzheimer\u2019s Network (DIAN), and the Genetic Frontotemporal dementia Initiative (GENFI). <\/span>Dr. Levin\u2019s work has contributed to the definition of the natural history, environmental factors, and symptomatic treatment of neurodegenerative diseases.<\/span><\/b> He holds a medical license and Doctor of Medicine from the LMU and is a board-certified neurologist at the Bavarian Chamber of Physicians (Landes\u00e4rztekammer Bavaria). Dr. Levin has published over 100 scientific publications in leading scientific journals. <\/p>\n<\/div><\/div><\/div>

Contact MODAG<\/p>\n<\/div>

Dr. Torsten Matthias, CEO<\/h4><\/div>

CEO<\/b><\/p>\n

Email:<\/b> info@modag.net<\/span>
Tel.: <\/b>+49 6734 96 228000<\/span><\/p>\n<\/div>

Contact media inquiries<\/p>\n<\/div>

Stephanie May<\/h4><\/div>

Trophic Communications<\/strong><\/p>\n

Email:<\/b> may@trophic.eu<\/span>
Tel.: <\/b>+49 171 185 56 82<\/span><\/p>\n<\/div>

Valeria Fisher<\/h4><\/div>

Trophic Communications<\/strong><\/p>\n

Email:<\/strong> fisher@trophic.eu<\/span>
Tel.:<\/strong> +49 175 804 18 16<\/span><\/p>\n<\/div>

\"MODAG<\/span><\/div>
<\/i>Download<\/span><\/a><\/div><\/div><\/div>

About MODAG: <\/span><\/h3><\/div>

MODAG, a privately held German biotech company,<\/span> aims to develop a novel approach for the treatment of neurodegenerative diseases by combining targeted small molecule therapeutics with novel diagnostic procedures.<\/span><\/h4><\/div>

Our primary goal is to demonstrate clinical proof-of-concept with our lead compound anle138b (emrusolmin) by preventing the progression of the disease process of multisystem atrophy (MSA) and thus develop a first disease-modifying therapy for synucleinopathies. This success will enable us to apply our technology to similar diseases with pathological protein aggregation, in particular Parkinson’s disease and, in the future, Alzheimer’s disease and tauopathies such as PSP. The aim is to dissolve disease-typical intracellular oligomers and thus reduce their toxic effects. MODAG was founded on the basis of inventions by scientists at the Ludwig Maximilian University of Munich and the Max Planck Institute for Biophysical Chemistry in G\u00f6ttingen and supported by research funding from leading patient organizations such as the Michael J. Fox Foundation for Parkinson’s Research, the Cure Parkinson’s Trust and Parkinson’s UK.<\/p>\n<\/div><\/div><\/div>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":3591,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[58],"tags":[],"class_list":["post-3765","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press"],"_links":{"self":[{"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/posts\/3765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/comments?post=3765"}],"version-history":[{"count":25,"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/posts\/3765\/revisions"}],"predecessor-version":[{"id":4970,"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/posts\/3765\/revisions\/4970"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/media\/3591"}],"wp:attachment":[{"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/media?parent=3765"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/categories?post=3765"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.modag.net\/en\/wp-json\/wp\/v2\/tags?post=3765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}